First-Line Therapies for VTE Treatment and Secondary Prophylaxis in Patients With Cancer: A New Direction.

Samantha M VogelLeticia V SmithEvan J Peterson

Published in: Journal of pharmacy practice (2018)

DOACs have the potential to bypass many challenges with traditional therapy. After analyzing the evidence available, we conclude that after careful consideration of risks and benefits, use of DOACs for VTE treatment are a reasonable option in patients with cancer.

Keyphrases

venous thromboembolism
direct oral anticoagulants
combination therapy
bone marrow